Imunon (IMNN) Competitors $0.95 +0.02 (+2.15%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends IMNN vs. VVOS, PLUR, LUMO, ALTS, EYEN, ELEV, BLRX, CELU, DARE, and LEXXShould you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Vivos Therapeutics (VVOS), Pluri (PLUR), Lumos Pharma (LUMO), Janone (ALTS), Eyenovia (EYEN), Elevation Oncology (ELEV), BioLineRx (BLRX), Celularity (CELU), Daré Bioscience (DARE), and Lexaria Bioscience (LEXX). Imunon vs. Vivos Therapeutics Pluri Lumos Pharma Janone Eyenovia Elevation Oncology BioLineRx Celularity Daré Bioscience Lexaria Bioscience Imunon (NASDAQ:IMNN) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and risk. Does the MarketBeat Community prefer IMNN or VVOS? Vivos Therapeutics received 1 more outperform votes than Imunon when rated by MarketBeat users. However, 100.00% of users gave Imunon an outperform vote while only 54.17% of users gave Vivos Therapeutics an outperform vote. CompanyUnderperformOutperformImunonOutperform Votes12100.00% Underperform VotesNo VotesVivos TherapeuticsOutperform Votes1354.17% Underperform Votes1145.83% Which has more volatility & risk, IMNN or VVOS? Imunon has a beta of 2.13, suggesting that its share price is 113% more volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.72, suggesting that its share price is 672% more volatile than the S&P 500. Does the media prefer IMNN or VVOS? In the previous week, Imunon had 4 more articles in the media than Vivos Therapeutics. MarketBeat recorded 4 mentions for Imunon and 0 mentions for Vivos Therapeutics. Vivos Therapeutics' average media sentiment score of 1.00 beat Imunon's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Imunon Neutral Vivos Therapeutics Positive Which has higher earnings and valuation, IMNN or VVOS? Vivos Therapeutics has higher revenue and earnings than Imunon. Imunon is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImunon$500K114.10-$19.51M-$1.92-0.49Vivos Therapeutics$13.80M0.93-$13.58M-$7.03-0.38 Do analysts rate IMNN or VVOS? Imunon currently has a consensus price target of $14.00, suggesting a potential upside of 1,373.68%. Vivos Therapeutics has a consensus price target of $6.60, suggesting a potential upside of 146.27%. Given Imunon's stronger consensus rating and higher probable upside, analysts plainly believe Imunon is more favorable than Vivos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Vivos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is IMNN or VVOS more profitable? Imunon has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -85.90%. Imunon's return on equity of -165.52% beat Vivos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ImunonN/A -165.52% -102.47% Vivos Therapeutics -85.90%-652.32%-98.95% Do insiders & institutionals believe in IMNN or VVOS? 4.5% of Imunon shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 5.0% of Imunon shares are owned by company insiders. Comparatively, 3.0% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryImunon beats Vivos Therapeutics on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNN vs. The Competition Export to ExcelMetricImunonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.05M$7.02B$5.33B$8.52BDividend YieldN/A7.92%5.07%4.13%P/E Ratio-0.4912.34128.5116.13Price / Sales114.10401.661,489.1693.42Price / CashN/A47.4339.6734.18Price / Book0.675.604.765.07Net Income-$19.51M$153.56M$119.00M$225.46M7 Day Performance2.43%0.13%0.79%0.54%1 Month Performance-4.98%15.20%5.64%3.75%1 Year Performance-4.77%41.11%36.71%29.48% Imunon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNNImunon3.411 of 5 stars$0.95+2.2%$14.00+1,373.7%-2.4%$57.05M$500,000.00-0.4933Upcoming EarningsNews CoverageGap UpVVOSVivos Therapeutics3.0549 of 5 stars$2.90+9.4%$6.60+127.6%-20.7%$13.83M$13.80M-0.41160Positive NewsPLURPluri0.7863 of 5 stars$4.32-1.1%N/A+14.4%$23.63M$330,000.00-0.73150Gap DownLUMOLumos Pharma3.2567 of 5 stars$4.45+1.1%$8.63+93.8%+21.4%$36.13M$2.05M-1.0030Upcoming EarningsHigh Trading VolumeALTSJanoneN/A$2.82+0.7%N/AN/A$35.50M$2.17M0.00170Short Interest ↑EYENEyenovia2.9442 of 5 stars$0.55+1.9%$12.00+2,081.8%-63.9%$35.23MN/A-0.6940ELEVElevation Oncology1.989 of 5 stars$0.60+1.7%$7.80+1,209.4%+23.2%$35.21MN/A-0.7040Upcoming EarningsBLRXBioLineRx2.2028 of 5 stars$0.44+7.4%$21.00+4,717.6%-72.2%$34.85M$17.05M-0.9740Analyst ForecastNews CoverageGap DownHigh Trading VolumeCELUCelularity0.0727 of 5 stars$1.71-8.1%N/A-33.1%$33.12M$33.52M0.00220Gap UpDAREDaré Bioscience1.6352 of 5 stars$3.91+7.1%$24.00+513.8%-15.4%$32.93M$2.84M-3.4930LEXXLexaria Bioscience3.2611 of 5 stars$2.52-4.9%$11.00+336.5%+60.0%$32.47M$411,019.00-5.737Short Interest ↓ Related Companies and Tools Related Companies VVOS Competitors PLUR Competitors LUMO Competitors ALTS Competitors EYEN Competitors ELEV Competitors BLRX Competitors CELU Competitors DARE Competitors LEXX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMNN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
